Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC

Biotechnology Research

Cardiff, Cardiff 4,175 followers

Advancing Medicines for a Brighter Future

About us

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Cardiff, Cardiff
Type
Public Company
Founded
2000

Locations

  • Primary

    1 Caspian Point

    Caspian Way

    Cardiff, Cardiff CF10 4DQ, GB

    Get directions

Employees at Biodexa Pharmaceuticals PLC

Updates

Similar pages

Browse jobs